<DOC>
	<DOCNO>NCT01518595</DOCNO>
	<brief_summary>The common observe cause gas exchange abnormality hypoxemia cirrhosis hepatopulmonary syndrome ( HPS ) report prevalence 20-47 % patient hepatic impairment cirrhosis . HPS far frequent respiratory complication cirrhosis . It progressive disease lead significantly increase mortality . Up date , therapeutic option liver transplantation . The study hypothesis administration bosentan patient liver cirrhosis suffer hepatopulmonary syndrome improve gas exchange . 18 patient liver cirrhosis fulfil criterion HPS accord ERS task force criterion include block randomize , double-blind , placebo control study ( 12 patient treated bosentan , 6 placebo ) . Patients receive bosentan 62,5mg b.i.d . 4 week 125 mg b.i.d . 8 week placebo . The duration treatment phase study 12 week . The primary endpoint alteration gas exchange 3 month therapy . The expected duration study 2 year .</brief_summary>
	<brief_title>Bosentan Treatment Hepatopulmonary Syndrome Patients With Liver Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hepatopulmonary Syndrome</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Presence HPS Age â‰¥ 18 year Intracardiac shunt Pregnancy Known hypersensitivity bosentan Use glyburide Use cyclosporin A Elevation aminotransferase level &gt; 3 time upper limit normal Use rifampicin Females childbearing potential without use adequate contraception Systolic blood pressure &lt; 85 mmHg Clinical relevant anemia HIVinfection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>patient</keyword>
</DOC>